12 February 2018

NHMRC has approved the recommendations made in the Evidence-based clinical practice guideline for deprescribing cholinesterase inhibitors and memantine developed by the University of Sydney in partnership with the NHMRC Cognitive Decline Partnership Centre and the Bruyère Research Institute in Canada. 


Cholinesterase inhibitors and memantine are two classes of drugs prescribed to reduce the symptoms of dementia. This guideline provides advice to healthcare professionals, people with dementia and their carers on when and how to withdraw these medications when the potential harms outweigh the benefits.